Multiple sclerosis: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• CD20 17
• CD19 9
• PPAR 0
• NLRP3 0
• STAT3 0
• BCMA 13
• NRF2 0
• TNF 0
• AQP4 0
• IL-17 0
• BTK 1
• GLP-1 2
• AMPK 0
• BDNF 1
• AKT 0
• IL-6 0
• mTOR 0
• CD40 0
• JAK 0
• PI3K 0
• STING 0
• TREM2 0
• PD-1 0
• IL-1 0
• IL-4 0
• SIRT1 0
• TLR4 0
• AXL 0
• CGRP 0
• CSF1R 0
• HIF-1 0
• IL-23 0
• VEGF 1
• COX-2 0
• CTLA-4 0
• CXCR4 0
• ERK 0
• HMGB1 0
• HSP90 0
• PD-L1 0
• TYK2 1
• APOE 0
• CCR5 0
• CTNNB1 0
• EGFR 0
• FOXP3 0
• GPX4 0
• IDO1 0
• JNK 0
• PARP 0
• PTEN 0
• TP53 1
• ACE2 0
• APP 0
• BCL-2 0
• BRD4 0
• C9orf72 0
• CDK4/6 0
• G6PD 0
• HDAC 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 9,555 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Withdrawn

  Acceptability and Feasibility of Transcranial Magnetic Stimulation (TMS) for Depression in Multiple Sclerosis

  NCT06329414· University of Utah· Updated 6 Nov 2026

  “Recruitment Failure”Registry text, quoted unchanged. Source

• Withdrawn

  Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases

  NCT07361094· Beijing Boren Hospital· Updated 15 Oct 2026

  “No participants.”Registry text, quoted unchanged. Source

• Withdrawn

  A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Autoimmune Diseases

  NCT07583030· Union Hospital, Tongji Medical College, Huazhong University of Science and Technology· Updated 2 Oct 2026

  “pipeline strategy change”Registry text, quoted unchanged. Source

• Withdrawn

  Testosterone Treatment for Erectile Dysfunction and Multiple Sclerosis

  NCT04601233· Tulane University· Updated 2 Oct 2026

  “The study didn't receive funding to move forward.”Registry text, quoted unchanged. Source

• Suspended

  A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease

  NCT04031469· ProgenaBiome· Updated 21 Sept 2026

  “Administrative”Registry text, quoted unchanged. Source

• Withdrawn

  Brain and Behavioral Influences on Motor Skill Learning in Multiple Sclerosis

  NCT03404388· Wayne State University· Updated 19 Aug 2026

  “This study did not receive funding and was therefore withdrawn prior to enrollment of participants.”Registry text, quoted unchanged. Source

• Terminated

  Feasibility of Remote Exercise Training for Hispanics/Latinos With MS

  NCT05998616· University of Illinois Chicago· Updated 7 Aug 2026

  “The study was terminated early due to NIH funding withdrawal before reaching the planned sample size of 50 participants. Thirty-three participants enrolled, 30 were randomized, and 26 completed follow-up assessments.”Registry text, quoted unchanged. Source

• Terminated

  A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT

  NCT03368664· Genzyme, a Sanofi Company· Updated 4 Aug 2026

  “Enrolment formally closed earlier than planned due to recruitment challenges.”Registry text, quoted unchanged. Source

• Suspended

  Study to Evaluate the Usability and Value of Integrated Digital Solutions in Medical Care of Participants With Multiple Sclerosis

  NCT05949580· Hoffmann-La Roche· Updated 20 Jul 2026

  “Transition of study Sponsor.”Registry text, quoted unchanged. Source

• Withdrawn

  RESET-MS: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Multiple Sclerosis

  NCT07006805· Cabaletta Bio· Updated 25 Jun 2026

  “The study was withdrawn prior to site activation and before enrollment of any participants due to sponsor decision to reprioritize the development portfolio.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Voluntary Activation During Isokinetic Contractions in Subjects With Neuromotor Disorders

  NCT04607174· Istituto Auxologico Italiano· Source

• Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis

  NCT07497399· Johns Hopkins University· Source

• Individualised Cryoneurolysis to Treat Pain in the Context of Spasticity in the Upper and Lower Extremities

  NCT07303582· Oxford University Hospitals NHS Trust· Source

• Efficacy of Split Gait in the Treatment of Dynamic Asymmetries in Subjects With Pathologic Claudication

  NCT04635436· Istituto Auxologico Italiano· Source

• A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis

  NCT07299019· Zenas BioPharma (USA), LLC· Source

• Motor Learning in Health and Movement Disorders: Role of Physical Activity and Advanced Devices

  NCT07066137· IRCCS Centro Neurolesi Bonino Pulejo· Source

• Wearable Focal Vibration Therapy on Upper Extremity Function of People With Multiple Sclerosis: A Pilot Study

  NCT07376772· University of Florida· Source

• A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis

  NCT07067463· Zenas BioPharma (USA), LLC· Source

• Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple Sclerosis

  NCT04480853· Novartis Pharmaceuticals· Source

• A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy

  NCT07609719· Genentech, Inc.· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 16
• Mendelian Randomization Analysis 66
• CRISPR-Cas Systems 3
• Gene Expression Profiling 38
• Sequence Analysis, RNA 6
• Whole Genome Sequencing 1
• Exome Sequencing 3
• Proteomics 34
• Metabolomics 21
• Mass Spectrometry 12
• Flow Cytometry 29
• Immunohistochemistry 10
• Xenograft Model Antitumor Assays 2
• Positron-Emission Tomography 28
• Magnetic Resonance Imaging 563
• Machine Learning 43
• Deep Learning 32
• Cohort Studies 182
• Genome-Wide Association Study 84

• Metabolomic Profiles Associated With Disease Severity in Multiple Sclerosis.

  Neurol Neuroimmunol Neuroinflamm, Oct 2026

• Spatial omics of neuroinflammation: insights across brain diseases.

  Front Immunol, Sept 2026

• Integrated multi-omics analysis identifies microbial and metabolic signatures and drivers of CNS autoimmunity.

  mSystems, Aug 2026

• Exercise-induced modulation of kynurenine pathway metabolite patterns in multiple sclerosis: a targeted metabolomics analysis across four randomized controlled trials.

  Brain Behav Immun, Jul 2026

• Bile acid metabolomics reveals distinct immunometabolic niches and enables accurate diagnosis of AQP4-IgG-seronegative NMOSD.

  Front Immunol, May 2026

• Sex-Specific Differences in Amino Acids and Neurotransmitters in Multiple Sclerosis Patients Compared to Non-Neuroinflammatory Controls: A Retrospective Case-Control Study.

  Neurochem Res, May 2026

• Investigation into the metabolomic effects of the non-canonical amino acid azetidine-2-carboxylic acid in neuroblastoma cells.

  Food Chem Toxicol, May 2026

• Serum metabolic profile at clinical onset as predictor of multiple sclerosis activity and progression after 5 years.

  Mult Scler, Apr 2026

• Aberrant long-chain fatty acids metabolism and its interplay with immuno-inflammatory responses in relapsing-remitting multiple sclerosis.

  Front Immunol, Mar 2026

• Research on metabolic characteristics of multiple sclerosis.

  Sci Rep, Mar 2026

See which targets of this disease your abstract mentions, and go to the people working on them.